|[September 18, 2013]
Research and Markets: PharmaSphere: Asia Pacific Deal Trends, 2004-2013
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/v67r96/pharmasphere)
has announced the addition of the "PharmaSphere:
Asia Pacific Deal Trends, 2004-2013" report to their offering.
The top 15 pharmaceutical and healthcare deals in the Asia-Pacific
(APAC) region during January 1, 2004 through June 1, 2013 were in the
categories of mergers and acquisitions (M&As), licensing agreements, and
collaborations and partnerships. These 15 deals represent a total value
of $51,397m, based on the assumption that the various agreed-upon
milestones have been achieved in order to ensure clarity and
standardization in the analysis presented in this report.
In terms of M&As, mergers among Japanese firms provided the most
impetus, with Takeda Pharmaceutical Company acquiring Nycomed as well as
Millennium Pharmaceuticals, both in record deals for a Japanese company,
and the Daiichi Sankyo merger.
Among the licensing agreement, the deal between the Danish firm
Lundbeck and Japan's Otsuka Pharmaceutical registered one of the highest
values at $1,800m, and focuses on the development and commercialization
of up to five innovative psychiatric and neuroscience products. The
partnership with the highest value was between Amgen and Takeda for
In terms of the split in the total deal value, M&As had the largest
share, representing more than half at 56%. The growing interest in the
APAC region is part of the shift in the industry dynamic towards the
emerging markets to boost revenue growth.
Licensing agreements take the second spot after M&As, with over 31% of
the total deal value. In this category, the deal structure and
motivation has predominantly been towards the licensing of product
candidates that are still undergoing clinical trials. The agreements
represent a mix of regional firms, particularly from Japan, seeking to
add to their research pipeline. Strategic collaborations and
partnerships come in at a distant third at 12.57%, representing the rest
of the total deal value.
The number of deals in the APAC region represents 32.6% of the total
deals globally between January 1, 2004 and June 1, 2013.
The largest number of deals involved drugs that are already marketed,
followed by Phase II, Phase III, and preclinical-stage drug candidates.
This trend indicates that one of the key areas of growth that
pharmaceutical firms are seeking in the APAC region is in marketing
drugs. Additionally, the interest in Phase II and Phase III drug
candidates is primarily from pharmaceutical firms in the region that are
seeking to boost their pipeline in a bid to increase their presence in
developed markets such as the US and the European Union (EU).
For more information visit http://www.researchandmarkets.com/research/v67r96/pharmasphere
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]